VeriTeQ’s Q Inside Safety Technology Meets the Direct Part Marking Requirement of the FDA’s Final Rule as an RFID Microtransponder for Unique Device Identification
DELRAY BEACH, Fla., July 29, 2015 (GLOBE NEWSWIRE) — VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets:VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that the Food and Drug Administration (the “FDA”) has released draft guidance that names radio frequency identification (“RFID”) as a technology solution to comply with the direct part marking requirements of the FDA’s final rule for unique device identification of medical devices. VeriTeQ’s Q Inside Safety Technology™ is an FDA cleared implantable RFID microtransponder that can be used to identify implantable and reusable/reprocessable medical devices.